Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on American Financial Tribune.
Press releases published on May 18, 2025
CAR Investors Have the Opportunity to Lead the Avis Budget Group Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
GlobeNewswire
·
May 18, 2025
Faruqi …
LPRO Investors Have the Opportunity to Lead the Open Lending Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
GlobeNewswire
·
May 18, 2025
Faruqi …
SANA Investors Have the Opportunity to Lead the Sana Biotechnology Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
GlobeNewswire
·
May 18, 2025
Faruqi …
NSSC Investors Have the Opportunity to Lead the Napco Security Technologies Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
GlobeNewswire
·
May 18, 2025
Faruqi …
Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress
GlobeNewswire
·
May 18, 2025
Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patients with Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions HEOR Analyses of Real-World Data Reveal Disparities in Outcomes In Females and Older Patients with Non- …
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
GlobeNewswire
·
May 18, 2025
Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM …
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
GlobeNewswire
·
May 18, 2025
Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-z Clinically meaningful improvements in ATTRv-PN related outcomes observed at 24 months compared to baseline, including in patients who were …